Late-onset doxorubicin-induced congestive heart failure in an elderly cancer survivor: A case report

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Makiko Suto¹  Hirotaka Suto²  Yumiko Inui³  Atsuo Okamura³ 

[1] Department of Cardiovascular Medicine, Takarazuka City Hospital, Hyogo, Japan;Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;Department of Medical Oncology/Hematology, Kakogawa Central City Hospital, Hyogo, Japan;Department of Medical Oncology/Hematology, Kakogawa Central City Hospital, Hyogo, Japan;

关键词: doxorubicin;    cardiotoxicity;    onco-cardiology;    cancer survivor;    elderly;    troponin I;    global longitudinal strain;   

DOI  :  10.3389/fcvm.2023.1124276

 received in 2022-12-15, accepted in 2023-04-11,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundRecently, the survival rate of patients with cancer has improved annually due to advancements in cancer diagnosis and treatment technologies. Meanwhile, late-onset complications associated with cancer treatment significantly affect survival and quality of life. However, different from pediatric cancer survivors, there is no unified view on the follow-up of late complications in elderly cancer survivors. We reported a case of congestive heart failure as a late-onset complication of doxorubicin (DXR) in an elderly cancer survivor.Case reportThe patient is an 80-year-old woman with hypertension and chronic renal failure. She received six cycles of chemotherapy for Hodgkin's lymphoma that started in January 201X-2. The total dose of DXR was 300 mg/m2, and a transthoracic echocardiogram (TTE) performed in October 201X-2, showed good left ventricular wall motion (LVWM). In April 201X, she suddenly developed dyspnea. Upon arrival at the hospital, a physical examination revealed orthopnea, tachycardia, and leg edema. A chest radiograph showed cardiac enlargement and pleural effusion. A TTE showed diffusely reduced LVWM and a left ventricular ejection fraction in the 20% range. After close examination, the patient was diagnosed with congestive heart failure due to late-onset DXR-induced cardiomyopathy.ConclusionLate-onset DXR-induced cardiotoxicity is considered high-risk from 250 mg/m2 or higher. Elderly cancer survivors are at higher risk of cardiotoxicity than non-elderly cancer survivors and may require closer follow-up.

【 授权许可】

Unknown   
© 2023 Suto, Suto, Inui and Okamura.